Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vx001 in TERT-positive NSCLC
NCT01935154Phase 2Completed
- Sponsor
- Vaxon Biotech
- Start
- Aug 2012
- Primary completion
- Jan 2017
- Modality
- Peptides, Therapeutic Vaccines
- Countries
- 8
01
Overview
A Phase 2 trial of vx-001 in non-small cell lung cancer (NSCLC), sponsored by Vaxon Biotech. Started Aug 2012; status: completed.
02
Drugs
vx-001
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01935154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01935154.